ACC 2022: Late-breaking Science Video Collection
Published: 05 April 2022
-
Views:
4069
-
Likes:
7
-
Views:
4069
-
Likes:
7
-
Up Next -
Part 3 | Session 13 ACC 22: Results From the Chocolate-Touch Study
-
Part 3 | Session 14 ACC 22: Results from the GIPS-IV Trial
-
-
-
-
Part 3 | Session 18 ACC 22: 3-year Efficacy Outcomes from the SPYRAL HTN-ON MED Med Pilot Study
-
Part 3 | Session 19 2022 AHA/ACC/HFSA Guideline for HF Management: Highlights & Implementation
-
Part 4 | Session 1 ACC 22: 3 Trials That Will Change Your Practice with Dr Purvi Parwani
-
-
Part 4 | Session 3 4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos
-
Part 1 | Session 1 ACC 22 Late-breaking Science Preview Nicolas M Van Mieghem, Joost Daemen
-
Part 1 | Session 2 ACC.22 Late-breaking Science Wrap-Up Nicolas M Van Mieghem, Joost Daemen
-
Part 2 | Session 1 ACC 2022 Late-breaker Discussion: The SODIUM-HF Trial Justin Ezekowitz, Harriette Van Spall
-
Part 2 | Session 2 ACC 2022 Late-breaker Discussion: The SuperWIN Trial Harriette Van Spall, Dylan L Steen
-
Part 2 | Session 3 ACC 22 Late-breaker Discussion: The PROMPT-HF Trial Harriette Van Spall, Gregg C Fonarow, Tariq Ahmad
-
Part 2 | Session 4 ACC 22 Late-breaker Discussion: The DIAMOND Trial Harriette Van Spall, Javed Butler, Faiez Zannad
-
Part 3 | Session 1 ACC 22: Findings from the VALOR-HCM Trial Milind Y Desai
-
Part 3 | Session 2 ACC 22: MAVA-LTE Shows Improvement in NYHA Class in Patients Treated with Mavacamten Florian Rader
-
Part 3 | Session 3 ACC 22: Results From the PACIFIC AF Trial Manesh R Patel
-
Part 3 | Session 4 ACC 22: FAME 3 Suggests CABG Outperforms FFR-Guided PCI in Patients with Multivessel Disease Frederik Zimmermann
-
Part 3 | Session 5 ACC 22: Results from the TRANSLATE-TIMI 70 Trial Brian Bergmark
-
Part 3 | Session 6 ACC 22: Results from the POISE-3 Trial Philip J Devereaux
-
Part 3 | Session 7 ACC 22: ICD Shock Therapies and the Burden of Ventricular Tachycardia Paolo Della Bella
-
Part 3 | Session 8 ACC 22: PACMAN-AMI Shows Reduced Plaque Regression in AMI Patients Treated with Alirocumab Lorenz Räber
-
Part 3 | Session 9 ACC 22: Magnitude & Duration of Effects of a siRNA Targeting Lp(a) Steven E Nissen
-
Part 3 | Session 10 ACC 22: Results From a sub-study of the POISE-3 Trial Maura Marcucci
-
Part 3 | Session 11 ACC 22: Findings from the CoreValve US Pivotal & SURTAVI Trials Michael J Reardon
Overview
Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data.
For a deeper dive into key clinical trial data, Dr Harriette Van Spall (McMaster University, Hamilton, CA)talks with principal investigators in her regular Late-Breaker Discussion Series.
Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
Part 1
View from the Thoraxcenter
In this concise episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their analysis of the late-breaking trials that will be presented at ACC 2022.
Part 2
Late-breaker Discussion Series
Host, Dr Harriette Van Spall interviews the late-breaker presenters of ACC Scientific Sessions 2022.
Part 3